VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | FIH study of ARV-110 in metastatic castrate-resistant prostate cancer

Sunandana Chandra • 11 Jun 2020
ASCO 2020
Warning: array_filter() expects parameter 1 to be array, bool given in /home/customer/www/vjoncology.com/public_html/wp-content/themes/vj/single.php on line 281

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discusses data from a first in human study of ARV-110, an androgen receptor PROTAC degrader in patients with metastatic castrate-resistant prostate cancer following enzalutamide and/or abiraterone. The study showed an acceptable safety profile and clinical activity in these patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter